Featured Speakers

Gross-Cary-260x260(Over)-Paying for Cancer Care

Cary Gross, MD, Professor of Medicine and Director of the Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine; co-author, A New Deal for Cancer Care: Lessons From a 50 Year War

Learn how the rise in cancer costs is attributable to a “cancer cost trifecta”—more cancers are being diagnosed, there is a higher utilization of cancer-related care, and there are now more expensive testing and treatment options available. Hear how a range of policy initiatives and reforms could help realign the interests of the scientists, providers, policy makers, and industry in order to prioritize patients and the public and reduce cancer costs. These include ramping up tobacco control efforts, supporting evidence-based prevention strategies (e.g., cervical cancer vaccination and colorectal cancer screening), and using payment reform to encourage high-value care. To reduce prescription drug spending, Gross supports the following measures: (1) expediting generic and biosimilar agents; (2) decoupling patient deductibles and co-pays from the cost of cancer care; (3) basing prices for new and existing therapies on their clinical benefits (“value-based pricing”); and (4) decoupling payer reimbursement from the FDA approval process.

About the Speaker:

Dr. Cary Gross is a Professor of Medicine and Public Health, and Director of the National Clinician Scholars Program at Yale. Dr. Gross completed his residency in Internal Medicine at New York Hospital-Cornell Medical Center and served as chief medical resident at Memorial Sloan-Kettering Cancer Center the following year. His research addresses comparative effectiveness, quality, and health equity, with a focus on cancer prevention and treatment. He is a founding Director of Yale’s Cancer Outcomes Public Policy and Effectiveness Research Center (COPPER). His research has been supported by the National Cancer Institute, the Agency for Healthcare Research and Quality, and the American Cancer Society, among others. As a former Robert Wood Johnson Foundation Clinical Scholar, Dr. Gross has advanced training in biostatistics, epidemiology, research ethics, and outcomes research.

Follow him on twitter: @cpgYale 

 

Levine-Harlan-260x260Deconstructing the Value Equation

Harlan Levine, MD, President, Strategy and Business Ventures, City of Hope National Medical Center

Cancer care is a complex—and often controversial—topic, with multiple stakeholders that view “value” through many different lenses. Hear what value in cancer care means to patients and their caregivers and how this meaning is usually different for payers and employers. Then consider how we define value in oncology reflects on us as a society. Strategize how these different perspectives fit together to yield a value equation that considers outcomes, patient experience, cost, and time…and yet it is not enough. Each stakeholder brings their own perspective to the relative value of these variables, resulting in solutions that address some issues while creating new ones. Hear about the role you can play in defining oncology value going forward, and in so doing, help drive to a better—and more equitable—cancer care delivery system.

About the Speaker:

Harlan Levine, MD, is president of strategy and business ventures for City of Hope. In this role, he is accountable for strategy, innovation and growth, drug commercialization, payer strategies and the Center for International Medicine. He also serves as the chairman of the board of AccessHope™, City of Hope’s subsidiary focused on serving the employer market and making leading-edge cancer care available to all regardless of geography.

Before City of Hope, Dr. Levine held executive roles at UnitedHealth Group, Towers Watson and Anthem Inc. He currently serves as a board member for Active Life Scientific, a board member and secretary for BioScienceLA, and a member of the Keck Graduate Institute’s Board of Trustees. In addition, he is a long-term strategic advisor to the Founder/CEO, now chairman of the board of Quantum Health, a member of the Accessibility and Affordability Working Group for California Institute for Regenerative Medicine, and a workgroup fellow for Health Evolution Forum’s New Models of Care Delivery.

Follow him on twitter: @drharlanlevine 

Co-Hosts

logo-ACCC-200x80logo-CCBD-200x80  logo-Foley&Lardener-200x80